Table 1.

Drugs and their mechanism as immune checkpoint inhibitors.

S. No.	Drug	Class	Rationale of Uses	References
1.	Nivolumab (Opdivo)	PD-1 inhibitors	Gastro-esophageal adenocarcinoma	[153]
2.	Cemiplimab (Libtayo)	PD-1 inhibitors	Advance cutaneous squamous-cell carcinoma	[154]
3.	Atezolizumab (Tecentriq)	PD-L1 inhibitors	Small- cell lung cancer	[155]
4.	Avelumab (Bavencio)	PD-L1 inhibitors	Advanced urothelial carcinoma	[156]
5.	Durvalumab (Imfinzi)	PD-L1 inhibitors	Biliary tract cancer	[157]
6.	Ipilimumab (Yervoy)	Cytotoxic T-lymphocyte antigen-4 (CTLA-4)	Advanced melanoma	[158]
7.	Tremelimumab (Imjuno)	Cytotoxic T-lymphocyte antigen-4 (CTLA-4)	Hepatocellular carcinoma	[159]
8.	Relatlimab	Lymphocyte Activation Gene-3 (LAG3; CD223)	Chronic lymphocytic leukemia (CLL)	[160]
9.	Opdualag	Lymphocyte Activation Gene-3 (LAG3; CD223)	Melanoma	[161]
10.	Indoximod	Indoleamine 2,3-dioxygenase (IDO-1) inhibitors	Advanced or metastatic melanoma	[162]
11.	Epacadostat	Indoleamine 2,3-dioxygenase (IDO-1) inhibitors	Renal cell carcinoma (RCC)	[163]
12.	Navoximod	Indoleamine 2,3-dioxygenase (IDO-1) inhibitors	Recurrent advanced solid tumors	[164]